A Novel Molecular Profile of Hormone‐Sensitive Prostate Cancer Defines High Risk Patients
The differential genetic signature identified between the two study groups revealed novel biomarkers in mHSPC, additionally suggesting new therapeutic targets within the hormone sensitive phase, such as AKT2. Further prospective larger cohort studies are needed to assess the prognostic value of our findings and their exact role in prostate cancer progression.
Authors
- Roberto Sabbatini (ORCID: https://orcid.org/0000-0002-8943-7545)
- Virginia Catani (ORCID: https://orcid.org/0000-0001-9508-7476)
- Stefania Ferretti (ORCID: https://orcid.org/0000-0002-2292-5632)
- Massimo Dominici (ORCID: https://orcid.org/0000-0002-4007-1503)
- Cinzia Baldessari (ORCID: https://orcid.org/0000-0003-3051-8057)
- Francesca Bacchelli
- Maria Giuseppa Vitale (ORCID: https://orcid.org/0000-0001-8551-266X)
- Claudia Piombino (ORCID: https://orcid.org/0000-0002-7224-4536)
- Albino Eccher (ORCID: https://orcid.org/0000-0002-9992-5550)
- Ilenia Mastrolia (ORCID: https://orcid.org/0000-0002-7742-8641)
- Cecilia Nasso (ORCID: https://orcid.org/0000-0003-1261-2269)
- Stefania Pipitone (ORCID: https://orcid.org/0000-0003-2677-1877)
- Stefania Bettelli (ORCID: https://orcid.org/0000-0002-3885-674X)
- Matteo Costantini
- Samantha Manfredini
Institutions
- University of Modena and Reggio Emilia (IT)
- Ospedale Santa Corona (IT)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/cam4.70472
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Ministero dell'Università e della Ricerca